Corbus Pharmaceuticals Holdings (FRA:3371) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3371 Corbus Pharmaceuticals Holdings Inc FRA:3371
35 GF Score
Price €7.90
GF Value €0.91
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Corbus Pharmaceuticals Holdings Defensive Interval Ratio?

FRA:3371
35GF Score
Corbus Pharmaceuticals Holdings Inc FRA:3371
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Corbus Pharmaceuticals Holdings (FRA:3371) Overvalued in 2026?

Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued. The current stock price of €7.90 is trading 768.1% above its estimated GF Value™ of €0.91. GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.

Key valuation signals for FRA:3371:

  • Defensive Interval Ratio:
  • GF Value™: €0.91 vs. price of €7.90 (768.1% above fair value)
  • GF Score™: 35/100 with 2 warning signs

No single metric tells the full story. See the FRA:3371 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK3371:Germany
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
35GF Score

Get the complete analysis for FRA:3371

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.90
Price
€0.91
GF Value